Adverse Events, Comorbidities, and HIV

Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.

Even with an undetectable viral load, study participants who had been vaccinated as children lost smallpox immunity.

Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.

Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.

Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.

The HIV services organization Housing Works implemented a hepatitis C treatment program in New York City, with very high completion rates.

Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.

Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.

Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.

In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.